Dean Maglaris is CEO and Chairman of the Board of Managers for Cytogel Pharma. Mr. Maglaris is a seasoned leader with more than 30 years in the pharmaceutical industry, joining Cytogel as its CEO in 2005. He has successfully guided the company through the identification of attractive compounds and the development of its lead compound, CYT-1010, which is entering Phase 2 clinical development, following a successful Phase 1 study in humans. Mr. Maglaris has long understood the need for a breakthrough solution to effectively and safely treat moderate to severe pain  and has recognized the potential benefits CYT-1010 could provide to patients. As such, Cytogel has a clear priority on developing this new class of drugs and continually pursuing new intellectual property, which has resulted in several issued patents.

Understanding the benefits that critical drug development can have on patients, Mr. Maglaris held leadership positions at Pfizer ranging from general management, product and business development and marketing.  His experience covers the spectrum of major therapeutic areas in pharmaceuticals as well as a wide array of medical device markets in the U.S. and worldwide. As Group Vice President and General Manager, he was instrumental in the development and launch of several products that became major successes, with several achieving annual sales in excess of $2.0 billion each.  He attributes that success to constantly focusing on discovering and developing drug solutions that actually address the needs of the patients and their providers, in a meaningful and comparatively better way.

Mr. Maglaris has been active in the industry and has participated as a member of the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization. He served as the Chair of the Board of Trustees of the University of Vermont, Chairman of the Board of Directors of the AmeriCares Foundation and an officer of the Board of Trustees of the New Canaan Country School in New Canaan, CT.  He holds a B.S. degree from the University of Vermont and an MBA from Northeastern University.

Steven G. Chrust is an outside manager on Cytogel's Board of Managers and is a member of the Compensation Committee.  He is founder and Senior Managing Partner of Centripetal Capital Partners, a private equity investment firm founded in 2004. He is also Founder and President of SGC Advisory Services, Inc., since 1991. Mr Chrust serves on several boards, including as Chairman of APJeT, Inc. and IMCS. He is a member of the Association for Investment Management and Research and the New York Society of Securities Analysts. He has lectured at the Harvard Business School and testified before Congress concerning the break-up of AT&T, and before state public utility commissions on various regulatory matters.

In 1994, he co-founded WinStar Communications, Inc., a facilities based local telecommunications provider utilizing fixed wireless technology and served as its Vice Chairman through 1998. Mr Chrust also served as Chairman of Worlds.com between 1999-2001.

Mr. Chrust began his career at Sanford C. Bernstein & Co., Inc., a financial institution handling more than $400 billion in client assets, now known as AllianceBernstein or AB. While at Bernstein, he was Director of Technology Research and ranked in the top tier of telecommunications analysts for more than a decade by Institutional Investor and ranked the #1 analyst in the sector for five consecutive years in their all-star ranking. Mr. Chrust is a graduate of Bernard M. Baruch College of the City University of New York and attended its business graduate school.

Cassandra Klimp is a founder and initial investor of Cytogel Pharma who has served as a non-executive director since 2006. She is a senior member of Meridian Partners LLC, a technology venture advisory firm,  with 30 years of experience in corporate banking, project management and entrepreneurship. Her career began in the field  for CL Peck Contractors in Los Angeles,  a design build firm  known for many of Los Angeles' storied  landmarks.  She segued into corporate lending for US Bank Corp, formerly First Bank Systems, where she financed commercial real estate development followed by years as a corporate lender to multibank holding companies in Minnesota, the Dakotas and Iowa in addition to working on divestiture of First Bank branches in the Dakotas.

Ms. Klimp has performed a range of advisory functions for profit and non-profit organizations with an emphasis on elder care and wellness issues.  She served on the board of directors of the Waveny Care Center, New Canaan, CT for eight years, co-chairing the design and construction of a state of the art Alzheimer wing which received national recognition.  Ms. Klimp is a native of Minnesota and a graduate of the University of Minnesota.

In a 30-plus year career with Deloitte, Jerry Leamon has held a variety of leadership positions including Global Managing Director responsible for the strategic direction of the firm's businesses. Throughout his career, he served some of the firm's largest and more complex clients.

Today, Jerry has the following current responsibilities: Chairman of the Board of Directors for Korn Ferry, where he previously chaired the compensation committee and was a member of the audit committee. He has been a member of the Korn Ferry Board since 2012.

Chairman of the audit committee for Credit Suisse USA pending its upcoming merger with UBS. Member of the Board of Geller & Co., a private business composed largely of a multi family ultra high net worth investment and advisory business. Audit committee Chair for Jackson Hewitt Tax Services, a private equity owned business.

Member of the Business Advising Council of the Carl H. Lindner School of Business at the University of Cincinnati. And has recently joined the Board of Managers for Cytogel.

Formerly, he was chairman of the Americares Foundation for 7 years and a board member for 17 years, and Trustee Emeritus of the University of Cincinnati Foundation.

Frederick W. Telling, PhD serves as an outside manager of Cytogel’s Board of Managers and is also a member of the Compensation Committee. Dr. Telling brings industry insight after serving Pfizer for 30 years. Dr. Telling was elected a Corporate Vice President of Pfizer Inc and its Vice President of Corporate Strategic Planning and Policy in October 1994. He oversaw the company's realignment and focus on its human and animal health business, divesting its Food Science and Medical Technology groups, while acquiring Warner Lambert, Pharmacia and various consumer product brands. Concurrently, Dr. Telling was responsible for the company's policy development and he represented the company in many industry-related outside Boards, including BIO where he served on its Board for over 10 years.

Dr. Telling is currently the Executive Chairman of Oragenics in Tampa, Florida and serves on the Compensation Committee and the Audit Committee.

He is Honorary Director and former Vice Chairman of the Board of the United Hospital Fund and an emeritus member of the Boards of several organizations with which he remains involved, including the National March of Dimes Foundation, EAA, ORBIS, and the Smithsonian National Air & Space Museum. Dr. Telling is the Chairman and CEO of the Reno Racing Association and President of theT-6 Racing Association and a member of The Metropolitan Club of Washington, DC.

Dr. Telling received his BA from Hamilton College and his Masters of Industrial and Labor Relations and PhD in Economics and Public Policy from Cornell University.

Michael Ullmann served as the Executive Vice President, General Counsel and Executive Committee Member of Johnson & Johnson (JNJ) for 11 years from 2012 until his retirement in 2023. As General Counsel of the world’s largest healthcare company, he successfully guided JNJ through high-profile and high-risk situations, while helping to grow the business, increase shareholder value and maintain its reputation as one of the most admired companies in the world. During his tenure as EVP, market cap increased from $177 to $450 billion and sales grew to $94 billion.

Over the course of his 11 years in role, Mr. Ullmann reported directly to three JNJ Chairman/CEO’s and worked closely with the JNJ Board of Directors, attending all Board meetings and providing strategic advice and driving successful results on Board matters, including ESG, investor activism, shareholder litigation, executive compensation, M&A, CEO transitions and geopolitical situations with significant financial and reputational risk. He also worked closely with the Audit, Compensation, Corporate Governance and Regulatory Compliance Committees of the Board.

Mr. Ullmann played a critical role in over 100 M&A transactions (totaling over $100 Billion) encompassing a range from multi-billion-dollar public company acquisitions and divestitures to venture capital investments, as well as the separation of JNJ’s iconic Consumer business. He also successfully led JNJ crisis management teams on high-profile and high-risk government investigations and regulatory actions, public relations and media situations, geopolitical events, litigation and product quality issues.

Mr. Ullmann led a global organization of over 2,000 employees in 60 countries encompassing Legal, Government Relations & Policy, ESG Strategy, Intellectual Property, Corporate Governance and the Risk Management areas of Data Privacy, Compliance and Security. He has had extensive experience in government affairs and public policy issues in Washington, D.C. focused on Congress and regulatory agencies (DOJ, FDA and SEC), as well as global experience in OUS markets, including, China, the EU, Asia and Latin America. In his Executive Committee role, he traveled to over 30 countries to meet with government officials, business partners and employees.

In the non-profit world, Mr. Ullmann serves as a Director and Audit Committee Chairman of Americares, the global healthcare and relief organization with over $1.5 billion provided in program services annually. He also serves as a Board member and Executive Committee member of the Princeton Area Community Foundation, a highly respected community foundation. In 2023, Mr. Ullmann joined the Board of the Naples Zoo, a nationally accredited zoo in Southwest Florida, which is also involved in conservation of wildlife and plants on a global basis.

Since retiring from Johnson & Johnson, Mr. Ullmann has also engaged in activities in the academic world related to innovation, research and leadership. At Massachusetts Institute of Technology (MIT), he was appointed by MIT's President to serve a four-year term on the MIT Visiting Committee for Sponsored Research, which serves as an advisory group on research activities sponsored by companies and the government. He has also been appointed to the MIT Sandbox Innovation Fund Board which is the primary MIT incubator program to support undergrad, graduate and postdoc students in the pursuit of their innovative and entrepreneurial ventures.

In Winter 2024, Mr. Ullmann was appointed as an Adjunct Faculty Member at Columbia Law School where he taught a seminar on the “Role of the General Counsel as a Business Leader.” He has also led workshops on ethical and values-based leadership at MIT and Columbia.

Before joining JNJ in 1989, Mr. Ullmann was an M&A transactional attorney in New York City. He is a magna cum laude graduate of Cornell University and received his law degree from Columbia University School of Law. Mr. Ullmann and his wife Lisa have three adult children and have lived in Princeton, New Jersey since 1991.